Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695291 | 0.78 | PTGS1 (0.51) | — | |
| SCHEMBL8089263 | 0.77 | PTGS2 (0.49) | MAPTCASP3 | |
| SCHEMBL2780142 | 0.77 | KIF11 (0.42) | KIF11CASP3FBP1BACE1L3MBTL1 | |
| SCHEMBL9812737 | 0.74 | MAPK14 (0.50) | MAPT | |
| SCHEMBL6498065 | 0.73 | PTGS1 (0.41) | KIF11APPCASP3L3MBTL1 | |
| SCHEMBL1825367 | 0.73 | BCAT2 (0.47) | BACE1 | |
| SCHEMBL6497992 | 0.72 | CYP2C8 (0.48) | KIF11APPBACE1 | |
| SCHEMBL16887409 | 0.71 | PLA2G10 (0.40) | MAPTL3MBTL1NISCH | |
| SCHEMBL13098291 | 0.71 | MAPK10 (0.56) | MAPTBACE1L3MBTL1 | |
| SCHEMBL8038496 | 0.71 | PTGS2 (0.51) | MAPTAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249137-A1 | PPAR active compounds | PLEXXIKON INC | 2008-10-09 | — | — | US | disclosed |
| US-20080249137-A1 | PPAR active compounds | PLEXXIKON INC | 2008-10-09 | — | — | US | disclosed |
| US-20080249137-A1 | PPAR active compounds | PLEXXIKON INC | 2008-10-09 | — | — | US | disclosed |
| EP-1940767-A2 | PPARACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007030567-A2 | PPARACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030567-A2 | PPARACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249137-A1 | PPAR active compounds | PPARG, PPARA, PPARD | KIF11 4491/4885MAPT 4530/4885APP 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.